PMID- 37012688
OWN - NLM
STAT- MEDLINE
DCOM- 20230405
LR  - 20230406
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 38
IP  - 13
DP  - 2023 Apr 3
TI  - Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, 
      Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean 
      Healthcare Workers.
PG  - e103
LID - 10.3346/jkms.2023.38.e103 [doi]
LID - e103
AB  - BACKGROUND: Although the primary vaccine coverage rate for coronavirus disease 
      2019 (COVID-19) in South Korea has exceeded 80%, the coronavirus continues to 
      spread, with reports of a rapid decline in vaccine effectiveness. South Korea is 
      administering booster shots despite concerns about the effectiveness of the 
      existing vaccine. METHODS: Neutralizing antibody inhibition scores were evaluated 
      in two cohorts after the booster dose. For the first cohort, neutralizing 
      activity against the wild-type, delta, and omicron variants after the booster 
      dose was evaluated. For the second cohort, we assessed the difference in 
      neutralizing activity between the omicron infected and uninfected groups after 
      booster vaccination. We also compared the effectiveness and adverse events (AEs) 
      between homologous and heterologous booster doses for BNT162b2 or ChAdOx1 
      vaccines. RESULTS: A total of 105 healthcare workers (HCWs) that were 
      additionally vaccinated with BNT162b2 at Soonchunhyang University Bucheon 
      Hospital were enrolled in this study. Significantly higher surrogate virus 
      neutralization test (sVNT) inhibition (%) was observed for the wild-type and 
      delta variants compared to sVNT (%) for the omicron after the booster dose (97%, 
      98% vs. 75%; P < 0.001). No significant difference in the neutralizing antibody 
      inhibition score was found between variants in the BNT/BNT/BNT group (n = 48) and 
      the ChA/ChA/BNT group (n = 57). Total AEs were not significantly different 
      between the ChA/ChA/BNT group (85.96%) and the BNT/BNT group (95.83%; P = 0.11). 
      In the second cohort with 58 HCWs, markedly higher sVNT inhibition to omicron was 
      observed in the omicron-infected group (95.13%) compared to the uninfected group 
      (mean of 48.44%; P < 0.001) after four months of the booster dose. In 41 HCWs 
      (39.0%) infected with the omicron variant, no difference in immunogenicity, AEs, 
      or effectiveness between homogeneous and heterogeneous boosters was observed. 
      CONCLUSION: Booster vaccination with BNT162b2 was significantly less effective 
      for the neutralizing antibody responses to omicron variant compared to the 
      wild-type or delta variant in healthy population. Humoral immunogenicity was 
      sustained significantly high after 4 months of booster vaccine in the infected 
      population after booster vaccination. Further studies are needed to understand 
      the characteristics of immunogenicity in these populations.
CI  - (c) 2023 The Korean Academy of Medical Sciences.
FAU - Lim, Sung Hee
AU  - Lim SH
AUID- ORCID: 0000-0003-0845-9994
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Kim, Han Jo
AU  - Kim HJ
AUID- ORCID: 0000-0002-5721-1728
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Cheonan Hospital, Cheonan, Korea.
FAU - Kim, Se Hyung
AU  - Kim SH
AUID- ORCID: 0000-0002-3426-1191
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Choi, Seong Hyeok
AU  - Choi SH
AUID- ORCID: 0000-0002-1280-7798
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Kim, Bora
AU  - Kim B
AUID- ORCID: 0000-0002-6836-4682
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Kim, Ji Youn
AU  - Kim JY
AUID- ORCID: 0000-0002-7605-801X
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Ji, Young Sok
AU  - Ji YS
AUID- ORCID: 0000-0001-8480-8952
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Kim, Tark
AU  - Kim T
AUID- ORCID: 0000-0002-8829-4183
AD  - Division of Infectious Disease, Department of Medicine, Soonchunhyang University 
      Bucheon Hospital, Bucheon, Korea.
FAU - Choo, Eun Ju
AU  - Choo EJ
AUID- ORCID: 0000-0003-2842-7041
AD  - Division of Infectious Disease, Department of Medicine, Soonchunhyang University 
      Bucheon Hospital, Bucheon, Korea.
FAU - Jung, Jung Chan
AU  - Jung JC
AUID- ORCID: 0000-0002-2036-0789
AD  - Department of Medical Biotechnology, Soonchunhyang University, Asan, Korea.
FAU - Moon, Ji Eun
AU  - Moon JE
AUID- ORCID: 0000-0002-7293-7463
AD  - Department of Biostatistics, Clinical Trial Center, Soonchunhyang University 
      Bucheon Hospital, Bucheon, Korea.
FAU - Kim, Chan Kyu
AU  - Kim CK
AUID- ORCID: 0000-0002-8002-5085
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Park, Seong Kyu
AU  - Park SK
AUID- ORCID: 0000-0002-3055-3621
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea.
FAU - Yun, Jina
AU  - Yun J
AUID- ORCID: 0000-0001-5897-8309
AD  - Division of Hematology-Oncology, Department of Medicine, Soonchunhyang 
      University, Bucheon Hospital, Bucheon, Korea. 19983233@schmc.ac.kr.
LA  - eng
GR  - 2023-0032/Soonchunhyang University/Korea
PT  - Journal Article
DEP - 20230403
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (BNT162 Vaccine)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Vaccines)
RN  - 0 (Antibodies, Viral)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - Humans
MH  - Antibody Formation
MH  - BNT162 Vaccine
MH  - *COVID-19/prevention & control
MH  - SARS-CoV-2
MH  - Antibodies, Neutralizing
MH  - Health Personnel
MH  - Republic of Korea
MH  - *Vaccines
MH  - Antibodies, Viral
PMC - PMC10070050
OTO - NOTNLM
OT  - Breakthrough Infection
OT  - COVID-19
OT  - Neutralizing Antibody
OT  - Omicron Variant
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2023/04/05 06:00
MHDA- 2023/04/05 06:42
PMCR- 2023/04/03
CRDT- 2023/04/04 01:22
PHST- 2022/08/12 00:00 [received]
PHST- 2022/12/27 00:00 [accepted]
PHST- 2023/04/05 06:42 [medline]
PHST- 2023/04/04 01:22 [entrez]
PHST- 2023/04/05 06:00 [pubmed]
PHST- 2023/04/03 00:00 [pmc-release]
AID - 38.e103 [pii]
AID - 10.3346/jkms.2023.38.e103 [doi]
PST - epublish
SO  - J Korean Med Sci. 2023 Apr 3;38(13):e103. doi: 10.3346/jkms.2023.38.e103.